Quantcast

Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations

July 24, 2014

“Highly concentrated formulations are the inevitable next generation of Parenteral Biologics.”

Sunnyvale, CA (PRWEB) July 24, 2014

Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced its feature in the BioProcess International article “Highly Concentrated Protein Formulations” by Jim Kling. Topics of this article include problematic issues with highly concentrated protein formulations and how automation can help address many of these problems.

High-concentration protein formulations have been a growing focus of pharmaceutical organizations in recent years. For example, these drug formulations would allow patients to perform injections themselves, instead of scheduling an inconvenient trip to the doctor each time an intravenous infusion treatment is needed.

However, protein aggregates, which can reduce potency or sometimes spur an immune-system response, have a higher likelihood of forming when higher concentrations are present. Formulations with high concentrations also are inclined to be more viscous, which can cause interference with the plunging motion of a prefilled syringe.

Issues like these require pharmaceutical companies to run hundreds of tests to find a solution. Problems with formulations normally do not cause a drug development program to fail. However, these issues can add valuable time and expenses to a program, sometimes limiting formulation applications for new drugs.

Automation can help reduce the impact of these time and expense impacts. For instance, one can use a small amount of material for testing, allowing one to test more formulations from a given batch. “It used to be that formulators would pick four formulations or so to move forward with,” said Dr. Russell Burge, Applications Scientist at Freeslate and contributor to the article. “But now with the high-concentration formulations, more testing may be necessary to ensure that the formulation in the final product is safe and effective, and more testing could also be necessary.”

Freeslate’s Biologics Formulation System allows pharmaceutical firms to develop more candidates, with more robust formulations, in a shorter period of time, with less material, and no increase in personnel. Freeslate has developed a single system that can support the entire formulation development process by combining liquid dispense and controlled heating/cooling/mixing with the introduction of new high throughput capabilities for pH measurement, viscosity measurement, and visual inspection/particle counting. Combined with Freeslate Lab Execution and Analysis (LEA) software, the Biologics Formulation System provides intuitive experiment design and allows for the control and data integration for a range of third party analytics including DLS, UV/Vis, cIEF, cSDS, HPLC, UPLC, etc. maximizing your R&D productivity.

Additional information on this article can be found by visiting the Bioprocess International website.

About Freeslate

Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12039350.htm


Source: prweb



comments powered by Disqus